Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/cf505f822a744ac9ab12008610c61b55 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:cf505f822a744ac9ab12008610c61b55 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:cf505f822a744ac9ab12008610c61b552021-12-02T14:40:13ZSynthetic viability by BRCA2 and PARP1/ARTD1 deficiencies10.1038/ncomms124252041-1723https://doaj.org/article/cf505f822a744ac9ab12008610c61b552016-08-01T00:00:00Zhttps://doi.org/10.1038/ncomms12425https://doaj.org/toc/2041-1723The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss.Xia DingArnab Ray ChaudhuriElsa CallenYan PangKajal BiswasKimberly D. KlarmannBetty K. MartinSandra BurkettLinda ClevelandStacey StaufferTeresa SullivanAashish DewanHanna MarksAnthony T. TubbsNancy WongEugen BuehlerKeiko AkagiScott E. MartinJonathan R. KellerAndré NussenzweigShyam K. SharanNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-12 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Xia Ding Arnab Ray Chaudhuri Elsa Callen Yan Pang Kajal Biswas Kimberly D. Klarmann Betty K. Martin Sandra Burkett Linda Cleveland Stacey Stauffer Teresa Sullivan Aashish Dewan Hanna Marks Anthony T. Tubbs Nancy Wong Eugen Buehler Keiko Akagi Scott E. Martin Jonathan R. Keller André Nussenzweig Shyam K. Sharan Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| description |
The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss. |
| format |
article |
| author |
Xia Ding Arnab Ray Chaudhuri Elsa Callen Yan Pang Kajal Biswas Kimberly D. Klarmann Betty K. Martin Sandra Burkett Linda Cleveland Stacey Stauffer Teresa Sullivan Aashish Dewan Hanna Marks Anthony T. Tubbs Nancy Wong Eugen Buehler Keiko Akagi Scott E. Martin Jonathan R. Keller André Nussenzweig Shyam K. Sharan |
| author_facet |
Xia Ding Arnab Ray Chaudhuri Elsa Callen Yan Pang Kajal Biswas Kimberly D. Klarmann Betty K. Martin Sandra Burkett Linda Cleveland Stacey Stauffer Teresa Sullivan Aashish Dewan Hanna Marks Anthony T. Tubbs Nancy Wong Eugen Buehler Keiko Akagi Scott E. Martin Jonathan R. Keller André Nussenzweig Shyam K. Sharan |
| author_sort |
Xia Ding |
| title |
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| title_short |
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| title_full |
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| title_fullStr |
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| title_full_unstemmed |
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies |
| title_sort |
synthetic viability by brca2 and parp1/artd1 deficiencies |
| publisher |
Nature Portfolio |
| publishDate |
2016 |
| url |
https://doaj.org/article/cf505f822a744ac9ab12008610c61b55 |
| work_keys_str_mv |
AT xiading syntheticviabilitybybrca2andparp1artd1deficiencies AT arnabraychaudhuri syntheticviabilitybybrca2andparp1artd1deficiencies AT elsacallen syntheticviabilitybybrca2andparp1artd1deficiencies AT yanpang syntheticviabilitybybrca2andparp1artd1deficiencies AT kajalbiswas syntheticviabilitybybrca2andparp1artd1deficiencies AT kimberlydklarmann syntheticviabilitybybrca2andparp1artd1deficiencies AT bettykmartin syntheticviabilitybybrca2andparp1artd1deficiencies AT sandraburkett syntheticviabilitybybrca2andparp1artd1deficiencies AT lindacleveland syntheticviabilitybybrca2andparp1artd1deficiencies AT staceystauffer syntheticviabilitybybrca2andparp1artd1deficiencies AT teresasullivan syntheticviabilitybybrca2andparp1artd1deficiencies AT aashishdewan syntheticviabilitybybrca2andparp1artd1deficiencies AT hannamarks syntheticviabilitybybrca2andparp1artd1deficiencies AT anthonyttubbs syntheticviabilitybybrca2andparp1artd1deficiencies AT nancywong syntheticviabilitybybrca2andparp1artd1deficiencies AT eugenbuehler syntheticviabilitybybrca2andparp1artd1deficiencies AT keikoakagi syntheticviabilitybybrca2andparp1artd1deficiencies AT scottemartin syntheticviabilitybybrca2andparp1artd1deficiencies AT jonathanrkeller syntheticviabilitybybrca2andparp1artd1deficiencies AT andrenussenzweig syntheticviabilitybybrca2andparp1artd1deficiencies AT shyamksharan syntheticviabilitybybrca2andparp1artd1deficiencies |
| _version_ |
1718390386852888576 |